Clinical trialNCT01730534CompletedPhase 3Interventional

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

SponsorAstraZenecaEnrollment17,190Diabetes Mellitus, Non-Insulin-DependentHigh Risk for Cardiovascular Event

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anna Maria Langkilde, MD
AstraZeneca Sweden
Study Director
clinicaltrials.gov ↗
Itamar Raz, MD
Hadassah Medical Organization
Principal Investigator
clinicaltrials.gov ↗
Marc S Sabatine, MD, MPH
TIMI Study Group, Boston, MA, USA
Study ChairKOL profile →
clinicaltrials.gov ↗
Stephen D Wiviott, MD
TIMI Study Group, MA, USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

805 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad Autonoma Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aire, Argentina
Research Site
Córdoba, Argentina
Research Site
Córdoba, Argentina
Research Site
Córdoba, Argentina
Research Site
La Plata, Argentina
Research Site
La Plata, Argentina
Research Site
Lanus, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Ramos Mejía, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
San Nicolás, Argentina
Research Site
Santa Fe, Argentina

Australia

Research Site
Adelaide - Oaklands Park, Australia
Research Site
Ashford, Australia
Research Site
Box Hill, Australia
Research Site
Camperdown, Australia
Research Site
Darlinghurst, Australia
Research Site
Fullarton, Australia
Research Site
Garran, Australia
Research Site
Geelong, Australia
Research Site
Heidelberg West, Australia
Research Site
Herston, Australia
Research Site
Joondalup, Australia
Research Site
Maroubra, Australia
Research Site
Melbourne, Australia
Research Site
Milton, Australia
Research Site
Murdoch, Australia
Research Site
Wollongong, Australia

Belgium

Research Site
Aalst, Belgium
Research Site
Antwerp, Belgium
Research Site
Bonheiden, Belgium
Research Site
Brasschaat, Belgium
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium

765 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dapagliflozin →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Apr 2013
Primary completion: 11 Sept 2018
Completion: 11 Sept 2018
Last update posted: 26 Dec 2019
Registered enrollment: 17,190
Registry id: NCT01730534

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.